Interview with Darren Ji, CEO, PharmaLegacy
Could you give us some personal background and tell us why you choose to come to the CRO side after a successful career at a multinational? A lot of people…
Address: Building 7, 388 Jialilue Rd.,Zhangjiang High-Tech Park, Shanghai,China
Tel: (86) 21-6100 2280
Web: http://www.pharmalegacy.com/Home.aspx?lang=en
PharmaLegacy Laboratories is a leading preclinical Contract Research Organization (CRO) providing specialty pharmacology services in Bone Metabolism, Immune Diseases, Inflammation, Oncology, and Orthopaedics and Tissue Engineering. The core competency of PharmaLegacy stems from our pioneering work and expertise in developing and running specialized animal models to test drug candidates and medical devices for their pharmacological effects and biocompatible repairs. We also conduct adjacency studies in PK/PD, molecular pharmacology and preliminary toxicology. Overall we provide one-stop shopping of preclinical pharmacology services for early proof of concept of therapeutics and fulfillment of regulatory requirement.
Aspiring to collaborate with our global clients to accelerate their missions to develop new therapies, PharmaLegacy provides quality services with faster turnaround and higher productivity of R&D to IND/IDE endeavors for pharmaceutical, biotech, and orthopaedic device companies around the world.
The PharmaLegacy management team consists of world-renowned scholars, top service scientists and seasoned business leaders from the US and Shanghai. We have fully established animal pharmacology models of rodents, rabbits, dogs, sheep, goats and non-human primates which are used to serve our current clients of large multinational pharmaceutical and medical device companies, as well as small- to-medium-sized biotech companies.
Research
Could you give us some personal background and tell us why you choose to come to the CRO side after a successful career at a multinational? A lot of people…
This week’s China healthcare roundup from PharmaBoardroom content partner Selesta highlights Kite Pharma’s US$1.64B in vivo CAR-T deal with Pregene, Xuanzhu Biopharma’s HKEX debut with a 172% grey market premium,…
This week’s China healthcare and pharma roundup from PharmaBoardroom content partner Selesta highlights CF PharmTech’s HKEX listing with a 227% grey market premium, Eccogene’s HKEX IPO filing at a US$500M…
In just four years, Shanghai-based Argo Biopharma has gone from a start-up to one of China’s most internationally recognised RNA innovators and has signed two major licensing deals with Novartis…
This week’s China healthcare and pharma roundup from PharmaBoardroom content partner Selesta highlights Sichuan Biokin and Binhui Biopharma’s HKEX IPO filings, Betta Pharma’s third IPO attempt, Sirius Therapeutics–B’s HK$1.8B IPO,…
This week’s China healthcare and pharma roundup from PharmaBoardroom content partner Selesta highlights GenFleet Therapeutics’ HKEX IPO, Sciwind’s IPO filing for enoglutide, Biocytogen’s STAR Market approval, Hengrui’s HER2 ADC licensing…
This week’s China healthcare and pharma roundup from PharmaBoardroom content partner Selesta highlights Atom Bioscience’s HKEX IPO, Ark Biosciences’ pipeline funding, Mabwell’s USD 1 billion siRNA deal, HiDiamond Bio’s Pre-Series…
3D Medicines has charted a deliberate path from domestic clinical execution to global oncology innovation. Since its IPO, the company has sharpened its focus on differentiated assets like Envafolimab, while…
This week’s China biopharma roundup from PharmaBoardroom content partner Selesta covers Legend Biotech’s planned secondary listing, Betta’s Hong Kong IPO move, iRegene’s USD 40mn raise after FDA Fast Track for…
This week’s China biopharma roundup from PharmaBoardroom content partner Selesta covers Novartis’ USD 5.4bn expansion with Argo in cardiovascular siRNA, Hengrui’s USD 1.1bn out-licensing of its cardiac myosin inhibitor, Novatim’s…
This week’s China healthcare and pharma roundup from PharmaBoardroom content partner Selesta covers Gilead’s USD 350mn bet on in vivo CAR-T, GenFleet and Bao Pharma advancing Hong Kong IPOs, Fosun’s…
Chinese biopharma innovators are making real progress toward global expansion. However, as Vera Zhang of Bristol-Myers Squibb (China) Investment Co., Ltd. writes in DIA’s Global Forum magazine, moving beyond exporting…
Jiangsu Hengrui Pharmaceuticals is no longer just a local biopharma heavyweight. With a record-breaking and 450x oversubscribed IPO raising USD 1.27 billion, a flurry of global licensing deals with the…
See our Cookie Privacy Policy Here
